PDF(Pubmed)
Abstract：
Background and objective The tumor\'s microenvironment is currently considered an important indicator of the tumor\'s prognosis, treatment failure, and recurrence. CD163+ tumor-associated macrophages (TAMs) are a marker of poor prognosis in many types of human cancers. In the present study, the expression of CD163+ TAMs was analyzed in laryngeal squamous cell carcinomas (LSCCs) using immunohistochemistry, and this expression was correlated with the clinical and pathological characteristics of LSCC patients. Materials and methods One commercial human larynx microarray with 80 cases of LSCCs, was used for this study. For comparison with normal laryngeal mucosa, a second microarray carrying normal tissues from all human anatomical sites, including normal laryngeal tissues, was used. Immunohistochemical staining was performed, and the primary antibody was a mouse monoclonal against human CD136. The absence of the primary antibody was used as a negative control. The percentage of positive cells was categorized into five scores: 0 (0%); 1, (1%-10%); 2, (11%-50%); 3, (51%-80%); and 4, (>80%). A case was scored as positive for CD163 with a score >= 1. The χ2 test was used to assess the CD163 expression in LSCC cases (N=80). A statistically significant difference was defined as P 0.05. Results The human larynx microarray containing 80 cases of LSCCs was used for this study. The age of the cancer patients in this array was in the range of 39 to 72, with a median of 53. LSCC grades were distributed as follows: 25 patients were designated as grade I, 43 were designated as grade II, and 6 were designated as grade III. Two tumors\' (2/80) cores were missing from the microarray. Six tumors on the microarray did not have a grade designation reported by the manufacturer of the array. The expression of CD163 in normal, benign, unmatched laryngeal tissue was absent. In cancer cases, on the other hand, a significant number of LSCCs had TAMs that were positive for CD163 (87% positive tumors, with an IHC score ranging from 1 to 4, χ2=30.634; p<0.001). The rest of the LSCC cases (10 in total) had negative CD163 expression (score of 0). Conclusion A significant majority of LSCCs were found to have CD163+ TAMs expression using tissue microarrays (TMAs). This expression is positively correlated with the tumor\'s grade, clinical manifestation, and TNM staging. Morphologic evidence shows that the majority of LSCCs express the highest range of immunohistochemistry (IHC) scores for CD163 protein in the membranes and cytoplasm of their TAMs. This study provides evidence of the clinical significance of CD163+TAMs in LSCCs and proposes further studies to pinpoint the exact role of these cells in LSCC patients.
摘要：
背景与目的肿瘤微环境目前被认为是肿瘤预后的重要指标,治疗失败,和复发。CD163+肿瘤相关巨噬细胞(TAM)是许多类型的人类癌症中预后不良的标志物。在本研究中,CD163+TAMs的表达在喉鳞状细胞癌（LSCCs）使用免疫组织化学，这种表达与LSCC患者的临床和病理特征有关。材料和方法一个商业人喉微阵列与80例LSCC，用于这项研究。与正常喉粘膜相比，第二个微阵列携带来自所有人体解剖部位的正常组织，包括正常的喉组织,被使用。进行免疫组织化学染色，主要抗体是抗人CD136的小鼠单克隆抗体。一级抗体的不存在用作阴性对照。阳性细胞的百分比被分类为五个得分:0(0%);1,(1%-10%);2,(11%-50%);3,(51%-80%);和4,(>80%)。一个病例的CD163评分为阳性，评分>=1。χ2检验用于评估LSCC病例中CD163的表达（N=80）。有统计学意义的差异定义为P<0.05。结果本研究使用包含80例LSCC的人喉微阵列。该阵列中癌症患者的年龄在39至72之间，中位数为53。LSCC分级分布如下：25例患者被指定为I级，43人被指定为二级，和6被指定为三级。微阵列中缺失了两个肿瘤核心(2/80)。微阵列上的六个肿瘤没有阵列制造商报告的等级名称。CD163在正常、良性,无匹配的喉组织。在癌症病例中，另一方面,大量的LSCCs具有CD163阳性的TAM（87％阳性肿瘤，IHC评分为1至4分，χ2=30.634；p<0.001）。其余的LSCC病例（共10例）CD163表达阴性（得分为0）。结论使用组织微阵列(TMA)发现绝大多数LSCC具有CD163+TAM表达。该表达与肿瘤的分级呈正相关,临床表现,和TNM分期。形态学证据表明，大多数LSCCs在其TAM的膜和细胞质中表达CD163蛋白的免疫组织化学（IHC）评分最高。这项研究提供了CD163TAM在LSCCs中的临床意义的证据，并提出了进一步的研究来确定这些细胞在LSCC患者中的确切作用。
